Bevacizumab has certain therapeutic effect on ovarian cancer, but due to the actual situation of patients and the degree of disease, the actual results of the use of the drug will be different, so it can not accurately judge the therapeutic effect.
Bevacizumab is a kind of vascular endothelial growth factor (VEGF) inhibitor, which is a more common targeted drug in clinic. As an anti-VEGF antibody, this drug can play a role in the treatment of many kinds of malignant tumors.
After diagnosed with ovarian cancer, women can use this drug to intervene under the guidance of doctors, some patients will experience symptom reduction, and some patients will develop drug resistance more quickly, so the treatment effect cannot be accurately judged.
It should be noted that ovarian cancer patients can reduce the adverse effects of the disease through “early detection, early diagnosis and early treatment”, and many patients may survive for a long time, so it is recommended that patients build up confidence in treatment.